Goldline Pharmaceutical Ltd (544759)
Latest quarterly results (Q4 FY26)
In its latest reported quarter, Q4 FY26, Goldline Pharmaceutical's revenue was ₹17.3 Cr, and net profit ₹2.8 Cr; the operating margin was 24.9%.
| Q4 FY26 (₹ Cr) | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹17.3 | — | — |
| Operating profit | ₹4.3 | — | — |
| Net profit | ₹2.8 | — | — |
| EPS (₹) | 4.00 | — | — |
| Operating margin | 24.9% | — | — |
📢 Recent Corporate Announcements
Goldline Pharmaceutical Ltd has received a disclosure under SEBI SAST Regulation 29(2) regarding insider share purchases. Promoter and Whole Time Director Mr. Swapan Khandelwal acquired 78,000 equity shares through the open market on August 28, 2026. This transaction represents approximately 0.81% of the company's total issued and paid-up share capital.
- Promoter & Whole Time Director Swapan Khandelwal acquired 78,000 equity shares
- Acquisition represents 0.81% of total paid-up share capital
- Transaction conducted via open market on August 28, 2026
- Disclosure filed pursuant to Regulation 29(2) of SEBI SAST Regulations, 2011
Swapan Khandelwal, Promoter and Whole Time Director of Goldline Pharmaceutical Ltd, acquired 78,000 equity shares via open market purchases on August 28, 2026. The transaction represents 0.81% of the company's total issued and paid-up equity share capital. Prior to this transaction, promoter shareholding stood at 57.29%. Open market accumulation by promoters typically indicates management confidence in the business.
- 78,000 equity shares acquired by Promoter and Whole Time Director Swapan Khandelwal
- Acquisition represents 0.81% of the total issued and paid-up share capital
- Transaction executed through open market on August 28, 2026
- Company reported FY26 revenue of Rs 31.20 Cr and net profit of Rs 4.12 Cr
Goldline Pharmaceutical has announced its 22nd Annual General Meeting (AGM) scheduled for August 29, 2026. In preparation, the company will close its Register of Members and Share Transfer Books from August 23 to August 29, 2026. The cut-off date for determining shareholder eligibility for the AGM is August 22, 2026. This is a standard regulatory procedure for listed entities to facilitate shareholder participation in the annual meeting.
- 22nd Annual General Meeting scheduled for Saturday, August 29, 2026, at 4:00 P.M.
- Book closure period defined from August 23, 2026, to August 29, 2026 (7 days inclusive).
- Cut-off date for member eligibility set as Saturday, August 22, 2026.
- Company's paid-up capital is confirmed at ₹9,60,00,000 consisting of 96 lakh equity shares.
Goldline Pharmaceutical has submitted its first Annual Report post-listing for FY 2025-26. The company reported a revenue of ₹31.2 Cr and a net profit of ₹4.12 Cr for the full year, showing growth from ₹28.01 Cr and ₹2.83 Cr respectively in FY25. The report outlines a portfolio of 146 products across five specialized divisions. The 22nd Annual General Meeting (AGM) is scheduled for August 29, 2026, to adopt financial statements and declare preference share dividends.
- FY26 Revenue reached ₹31.2 Cr, a 11.4% increase from ₹28.01 Cr in FY25
- Net Profit for FY26 stood at ₹4.12 Cr, up from ₹2.83 Cr in the previous year
- The company manages a portfolio of 146 products across 5 specialized divisions (Pharma, Cardinal, Aayushman, In Life, Wellness)
- Successfully listed on the BSE SME Platform on May 19, 2026
- AGM scheduled for August 29, 2026, with a shareholder cut-off date of August 22, 2026
Goldline Pharmaceutical has issued a notice for its 22nd AGM on August 29, 2026, proposing significant financial resolutions. The company seeks shareholder approval to borrow up to ₹200 Cr from directors, with a provision to convert these unsecured loans into equity shares. This limit is highly material, representing approximately 6.4x the company's FY26 revenue of ₹31.2 Cr. Additionally, the company is seeking a ₹200 Cr limit for loans and guarantees to entities where directors are interested, alongside ratifying material related party transactions.
- Proposed borrowing limit of ₹200 Cr from directors, which is ~14x the current net worth of ₹14 Cr
- Provision for converting director loans into fully paid-up equity shares at SEBI-regulated prices
- Approval sought for loans, investments, or guarantees up to ₹200 Cr under Section 185 for subsidiaries/associates
- Ratification of material related party transactions with Activista Healthcare, Nucleage Pharma, and Numerius Healthcare
- FY26 annual revenue stood at ₹31.2 Cr with a net profit of ₹4.12 Cr
Mr. Prashant Shrikrishna Karkare, an Executive Director of Goldline Pharmaceutical Ltd, acquired 27,000 equity shares on July 28, 2026. This transaction represents 0.28% of the company's total issued and paid-up share capital and was conducted through the open market. Insider buying of this nature is typically viewed as a sign of management confidence in the company's valuation and future prospects. The company reported a net profit of ₹4.12 cr on a revenue of ₹31.2 cr for FY26.
- Acquisition of 27,000 equity shares by Executive Director Prashant Shrikrishna Karkare
- The purchase represents 0.28% of the total issued and paid-up share capital
- Transaction executed on July 28, 2026, through the open market
- Company reported FY26 revenue of ₹31.2 cr and PAT of ₹4.12 cr
Goldline Pharmaceutical Ltd has appointed M/s. Avinash Prakash Gandhewar as its Secretarial Auditor for the financial year 2025-26. The appointment was approved by the Board of Directors in a meeting held on July 14, 2026. The auditor is a peer-reviewed firm with expertise in Company Law, Securities Laws, and SME IPOs. This is a standard regulatory compliance filing under SEBI (LODR) Regulations.
- Appointment of M/s. Avinash Prakash Gandhewar as Secretarial Auditor for FY 2025-26
- Board approval granted on July 14, 2026, for the audit of the period ending March 31, 2026
- The auditor holds Membership No. FCS 11197 and is a peer-reviewed firm
- Scope of audit includes compliance with Company Law, FEMA, and Securities Laws
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
